Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - formoterol fumarate dihydrate, quantity: 6 microgram; beclometasone dipropionate, quantity: 200 microgram; glycopyrronium bromide, quantity: 12.5 microgram (equivalent: glycopyrronium, qty microgram) - inhalation, pressurised - excipient ingredients: ethanol absolute; norflurane; dilute hydrochloric acid - asthma trimbow 200/6/10 maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - metyrapone, quantity: 250 mg - capsule, soft - excipient ingredients: macrogol 400; sodium ethyl hydroxybenzoate; sodium propyl hydroxybenzoate; macrogol 4000; glycerol; gelatin; purified water; acetanisole; ethyl vanillin; titanium dioxide; propylene glycol; hypromellose; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - diagnostic use,? for the diagnosis of latent acth deficiency such as in cases of known pituitary dysfunction or of a suspected pituitary tumour, as well as before and after surgical intervention in the region of the pituitary; and, to assess the degree of acth suppression during or after glucocorticoid therapy.,? for the differential diagnosis of states of adrenocortical hyperfunction in cushing's syndrome.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - budesonide, quantity: 3 mg - capsule, modified release - excipient ingredients: sodium lauryl sulfate; iron oxide yellow; tributyl acetylcitrate; colloidal anhydrous silica; titanium dioxide; liquid paraffin; dimeticone 1000; purified talc; iron oxide black; ethylcellulose; gelatin; triethyl citrate; methacrylic acid copolymer; iron oxide red; polysorbate 80; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide; maize starch; sucrose - the induction of remission in adult patients with mild to moderate crohn's disease affecting the ileum and/or the ascending colon.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - hydrocortisone, quantity: 5 mg - granules - excipient ingredients: microcrystalline cellulose; hypromellose; magnesium stearate; ethylcellulose - replacement therapy of adrenal insufficiency

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - hydrocortisone, quantity: 2 mg - granules - excipient ingredients: microcrystalline cellulose; hypromellose; magnesium stearate; ethylcellulose - replacement therapy of adrenal insufficiency

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - hydrocortisone, quantity: 1 mg - granules - excipient ingredients: microcrystalline cellulose; hypromellose; magnesium stearate; ethylcellulose - replacement therapy of adrenal insufficiency

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - hydrocortisone, quantity: 0.5 mg - granules - excipient ingredients: microcrystalline cellulose; hypromellose; magnesium stearate; ethylcellulose - replacement therapy of adrenal insufficiency.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - beclometasone dipropionate, quantity: 200 microgram; formoterol fumarate dihydrate, quantity: 6 microgram - inhalation, pressurised - excipient ingredients: norflurane; ethanol absolute; hydrochloric acid - asthma fostair is indicated in adults (18 years and older) in the treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids (ics) and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both ics and long-acting beta2-agonists (laba). (see section 4.2 dose and method of administration for treatment approaches).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - cannabidiol, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: sesame oil; sucralose; ethanol absolute; flavour - epidyolex is indicated for use as adjunctive therapy of seizures associated with lennox-gastaut syndrome (lgs) or dravet syndrome (ds) for patients 2 years of age and older.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - nabiximols, quantity: 80 mg/ml - spray, solution - excipient ingredients: propylene glycol; peppermint oil; ethanol absolute - sativex is indicated as treatment, for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (ms) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.